Archives

+

Folium Biosciences Submits Novel Food Application for CBD in the UK

March 24, 2021|Blog, Media, News | 2 Min Read

Colorado Springs, Colo. – March 15, 2021 – Folium Biosciences has submitted a novel food application to the UK Food Standards Agency (FSA) for validation of its hemp-derived, 0.0% THC […]

Read More
by
+

One Year After Securing API License for Pharma Grade CBD, Folium Biosciences Reports Broad Global Pharmaceutical Adoption

October 16, 2020|Media, News | 2 Min Read

Folium’s CBD API is an essential ingredient in pharmaceutical formulations worldwide. Colorado Springs, Colo. – October 15, 2020 – Since securing its Active Pharmaceutical Ingredient (API) license one year ago, […]

Read More
by
+

Global Veteran Specialty Ingredient Sales Executive Kris High Joins Folium Biosciences as Chief Commercialization Officer

September 16, 2020|Media, News | 3 Min Read

After two decades of global sales leadership in the specialty food and ingredient sectors, Kris High has joined the executive team at hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences as the company’s first Chief Commercialization Officer

Read More
by
+

Broad Spectrum Stalk CBD Oil

September 14, 2020|Blog, Media, News | 2 Min Read

Folium Biosciences Introduces Broad Spectrum Stalk CBD Oil to Meet Global Demand from Stalk-and-Seed Countries Stalk-and-Seed Formulation Secures Approval for Distribution in Japan and South Korea. Folium Biosciences introduces Broad […]

Read More
by
+

Tricia DiPersio, PhD, RD, Joins Folium Biosciences as EVP of Quality, Compliance & Customer Relations

September 14, 2020|Media, News | 3 Min Read

Food, beverage and supplements industry veteran Tricia DiPersio, PhD, RD, has joined the executive team at Folium Biosciences as the company’s first EVP of Quality, Compliance and Customer Relations.

Read More
by
+

Kandy Anand Joins Folium Biosciences Board of Directors

August 27, 2020|Media, News | 3 Min Read

Colorado Springs, Colo. – September 9, 2020 – Hemp-derived, non-psychoactive cannabinoid manufacturer Folium Biosciences welcomes Kandy Anand, former Chief Growth Officer at Molson Coors Brewing Company (NYSE: TAP), to its […]

Read More
by
+

Folium Biosciences Names Nutralliance a Preferred U.S. Distributor of Company’s Hemp-Derived Non-Psychoactive Cannabinoid (CBD) Products

August 25, 2020|Media, News | 2 Min Read

Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences and premium-ingredient sales and marketing company Nutralliance have entered a distribution partnership that grants Nutralliance the right to distribute Folium’s industry-leading 0.0% THC broad spectrum CBD oil products in the United States, and establishes Folium as Nutralliance’s exclusive CBD supplier.

Read More
by
+

Folium Biosciences Completes Construction of One of the World’s Largest Cannabinoid Extraction and Purification Facilities in Pueblo West, CO

August 12, 2020|Media, News | 3 Min Read

Folium Biosciences has completed buildout and received a Certificate of Occupancy for the world’s largest cannabinoid extraction and purification facility, located in Pueblo West, Colo.

The new 110,000-square-foot Pueblo West facility will produce up to 22,000 kg of 0.0% THC broad spectrum CBD oil each month. To satisfy accelerating demand from CBD product manufacturers worldwide, the plant has dedicated production lines to meet CBD regulatory requirements in the US, EU, Japan, and South Korea, among other countries.

FDA registered and state-of-the-art, the new Folium facility is purpose-built for extraction, purification and formulation of cannabinoids and terpenes. The plant will utilize supercritical carbon dioxide (sCO2) extraction technology exclusively to produce phytocannabinoid-rich 0.0% THC broad spectrum CBD oil, adhering to a continuous process from decarboxylation to extraction that allows for a revolutionary inline terpene capture system.

Read More
by
+

Folium Biosciences’ General Counsel, Craig Brand Presents Closing Remarks at FDA Hearings on CBD

May 31, 2019|Media, News | 1 Min Read

The FDA is taking its first step in setting new regulations for cannabis Friday, holding a public hearing to dive into what its regulatory strategy should address. FDA Commissioner Scott Gottlieb has expressed concerns about companies making claims of the health benefits of CBD. But he also recognizes regulations are needed to provide clarity for companies that want to market cannabis products. Potential safety issues are expected to be a major topic at the hearing. (Fox Business)

Read More
by

Global Hemp Leader Folium Biosciences Diversifies CBD-Infused Cosmetic Line

April 19, 2019|Media, News | 2 Min Read

Click button below to view Cosmeceutical Release. COLORADO SPRINGS, Colo., March 26, 2019 /PRNewswire/ — Global hemp leader Folium Biosciences has been an industry innovator of hemp derived 0.0% THC, phytocannabinoid-rich (PCR) […]

Read More
by